Mesoblast targets AMD and retinopathy

By Dylan Bushell-Embling
Thursday, 10 July, 2008

Mesoblast [ASX: MSB] today released results from its sister company Angioblast's pre-clinical trials into using adult stem cells to treat ocular diseases association with abnormal blood vessels.

Trials involving 42 non-human primates indicates that an injection of Mesoblast's proprietary adult stem cells combined with an anti-VEGF agent were able to reduce the number of leaking blood vessels - a major cause of ocular disease - more effectively than using an anti-VEGF agent alone.

The combination also reduced the number of subsequent anti-VEGF injections required in the primates.

The results of this trial will comprise part of the company's IND application to the US FDA.

Related News

Novel antibiotic activates 'suicide' mechanism in superbug

Researchers have discovered a new class of antibiotic that selectively targets Neisseria...

Modifications in the placenta linked to psychiatric disorders

Schizophrenia, bipolar disorder and major depression disorder are the neuropsychiatric disorders...

ADHD may be linked with an increased risk of dementia

An adult brain affected by attention deficit hyperactivity disorder (ADHD) presents modifications...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd